Tesofensine

Key Research Papers and Clinical Trials

Research on tesofensine spans multiple therapeutic areas, with studies examining its mechanisms of action, metabolism, and clinical applications primarily in obesity and neurological conditions.

Mechanism and Pharmacology Studies

Recent research has provided insights into tesofensine's structural basis as a triple reuptake inhibitor (Nature Communications, 2025) and its effects on brain function. A 2024 study in PLoS One demonstrated that tesofensine silences GABAergic neurons in the hypothalamus, which may explain its appetite-suppressing effects. Additional preclinical work has examined sex-specific effects on behavior in animal models (PLoS One, 2025) and drug metabolism pathways in humans (Drug Testing and Analysis, 2026).

Clinical Trials in Obesity

The most substantial clinical evidence comes from obesity research. A randomized controlled trial published in the European Journal of Endocrinology (2022) specifically examined Tesomet (a combination of tesofensine and metoprolol) for weight loss in hypothalamic obesity, though specific sample sizes and detailed results are not provided in the available abstracts.

Clinical Trial Program

The clinical development program includes several completed studies:

• Phase 1/2 energy balance study (NCT00428415): Examined tesofensine's effects on energy balance in humans
• Phase 2 hypothalamic obesity study (NCT03845075): A 48-week safety and tolerability study of tesofensine/metoprolol combination in subjects with hypothalamic injury-induced obesity
• Phase 2 diabetes study (NCT02737891): Evaluated safety and efficacy in type 2 diabetes patients
• Phase 1 cardiac safety study (NCT03488719): Examined effects on 24-hour heart rate when combined with metoprolol

Notably, one Phase 2 trial (NCT00148486) investigated tesofensine (referred to as NS 2330) in early Parkinson's disease, reflecting its original development as a neurological treatment before obesity applications.

Evidence Limitations

While multiple studies have been completed, detailed results and sample sizes are not available from the provided abstracts. The clinical evidence base appears focused on combination therapy with metoprolol rather than tesofensine alone, particularly for obesity indications.

This synthesis is based on study titles and basic trial information only. Consult published full-text articles and speak with healthcare providers for comprehensive clinical information.